Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
about
Epidemiology and clinical course of Crohn's disease: results from observational studiesAdverse effects of biologics: a network meta-analysis and Cochrane overviewThalidomide and thalidomide analogues for maintenance of remission in Crohn's diseaseThalidomide and thalidomide analogues for induction of remission in Crohn's diseaseTumor necrosis factor-alpha antibody for maintenance of remission in Crohn's diseaseInflammatory bowel disease surgery in the biologic eraUse of biologics and chemotherapy in patients with inflammatory bowel diseases and cancerSelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabDiagnostic imaging advances in murine models of colitis.Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Current stage in inflammatory bowel disease: What is next?Pharmacologic therapy for inflammatory bowel disease refractory to steroidsOptimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug WithdrawalReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesInflammatory pathways of importance for management of inflammatory bowel diseaseRedeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel diseaseUse of the tumor necrosis factor-blockers for Crohn's diseaseTHERAPIES FOR CROHN'S DISEASE: a clinical updateThe Role of Laboratory Tests in Crohn's DiseaseCurrent therapy of pediatric Crohn's diseaseDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabSystematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.Inflammatory bowel disease and celiac disease: overlaps and differences.Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysisUse of thiopurines in inflammatory bowel disease: Safety issues.Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran populationUncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.Impact of pain on health-related quality of life in patients with inflammatory bowel diseaseEfficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory SarcoidosisAdalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.
P2860
Q22241217-92653856-646D-4E16-A4EB-385DAAD9D21DQ24234197-2F0A2FDF-578B-4466-ADE1-B87CE4E1C110Q24241489-2D2B45FB-7CA5-4824-98EB-4AA65D09DD2AQ24241766-4F6C0423-420A-4C8B-9750-B1D5E83A86E9Q24242101-4564828B-3DFC-4867-BE39-465EB0B2BD14Q26745627-98BD947B-9E8A-49EA-9E15-7841D43562E7Q26750190-288CBB43-A7AA-408B-B7B4-1010A8923F63Q26750456-A11B3CAE-F463-47F2-8534-501AD20226B6Q26774583-87E63BAA-7D02-44FC-AF96-5F8B69E74EF9Q26775240-6345ED89-0623-402E-A979-9271119B93BEQ26777409-87644B49-EDC2-4FD6-B713-CFB905326FE6Q26777429-B8B1F8BF-B9E2-4FF6-BE0A-12628CD9A443Q26796415-A35A1138-19D9-4138-BE8C-42418DB0264CQ26801119-54DCB3F8-883A-4DE0-9945-C8FD547E3428Q26822029-395B2926-0204-42EE-B537-C4FEE24A41C3Q26829488-76118739-DA79-4633-8A97-19DBE3DEE34FQ26991673-E098C3DB-CDCA-47FE-95A3-10BEDEC5B344Q27005445-8AFDC51A-8863-436D-8F95-9B7717915BBDQ27027630-FD43012A-2E44-445F-8F2B-670127DFB0F3Q27030762-A325C47B-3192-49D5-8C11-5985F553DD70Q28070271-FAE85140-BC9A-4C88-B48C-3AE22A341C37Q28075045-02786C47-72B3-4B0C-852D-876AF834FCDFQ28081919-1BD07265-0BA5-42E1-8DC8-FFB6211D7E0AQ28083872-F0FF6CDA-6E59-4CEC-9FB8-8B8AAAD6C9B5Q30234628-DB75BC2E-1E4F-4EF1-A01A-AAB3DB1D84BEQ30242073-0BBD9C64-FC5C-4FA4-885B-EAF585EB98D3Q30679247-AACE2CF1-6D71-4721-98C1-A4CBCAB0D5C1Q33362566-9ADCC73F-4B64-4ABD-82F6-043E4827552DQ33562796-E5632A2D-0B53-47E5-9425-09EE5782BC6CQ33564085-296D92FD-E751-422E-BEB0-3ECD0AE52BF0Q33564492-3B767611-215D-4990-8403-6E7E1561FE0BQ33621267-44A56157-2EBB-4B87-B702-D3B66948F2E5Q33667897-B21B67D4-0131-4F27-8364-3B24014C797EQ33711741-66FD7294-4ACA-4571-8A7F-5BC69B505D19Q33756929-79134E53-9EDD-4155-9B42-58B392349B66Q33874790-E34A8202-C39C-4F6E-A643-6FD6788F9278Q33933336-4BC1C4EE-1E7B-44F4-964E-8C7C8E54F5E9Q33960394-BCACAE2B-3013-4278-B0D3-EB9879A6F5ADQ34050113-383FF44C-3871-4A7B-B781-CA8A227A35EDQ34100121-99143100-AE59-4103-876B-9CD2571E92B7
P2860
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 February 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
@en
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
@nl
type
label
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
@en
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
@nl
prefLabel
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
@en
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
@nl
P2093
P2860
P356
P1433
P1476
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
@en
P2093
D G MacIntosh
P F Pollack
P Rutgeerts
R Panaccione
S B Hanauer
W J Sandborn
P2860
P304
P356
10.1136/GUT.2006.106781
P407
P577
2007-02-13T00:00:00Z